Out-licensing: Generic Version Of Naltrexone 50 Mg Film Tablet:

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

Generic version of Naltrexone 50 mg film tablet:

Opioid receptor blocker which reduces desire for opioids and alcohol, use in psychiatry, neurology and addition medicine.

Mechanism of action

Competitive Blocker of mü, kappa and delta opioid receptors.

Full description

An oral opioid antagonist for abstinence-oriented treatment of former opioid and alcohol-addicts. Target groups are Drug Treatment Centres, psychiatrists and physicians treating former opioid- and alcohol addicts.

Development status

Registered

Patent information

Off patent

Type of business relationship sought

Country-specific or regional distribution contract

Licensing contact

Dr. Juerg Fehlmann
Business Development Manager

Contact directly

Company details

Orpha Swiss GmbH

OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Potent Pharmacophoric Delta- and Mu-Opioid Receptor Antagonists and Conversion of Endomorphin Mu-Opioid Agonists to Antagonists

Benztropinamine Analogs as Dopamine Transport Inhibitors

Buprenorphine 0.4 - 2 - 8 mg Sublingual Tablets

Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor

Related categories

Industry sector: Pharmaceutical / Generics; Pharmaceutical / Prescription
Therapeutic target: Central Nervous System / Psychiatric / Addiction; Central Nervous System / Psychiatric / Alcoholism; Central Nervous System / Psychiatric / Cocaine addiction; Central Nervous System / Psychiatric / Opioid dependency

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us